

## The Prevalence and Antimicrobial Resistance of *Campylobacter Jejuni* and *Campylobacter coli* in Chicken Livers Used for Human Consumption in Ecuador

<sup>1</sup>Rosa Janneth Simaluiza, <sup>1</sup>Zorayda Toledo, <sup>1</sup>Sofia Ochoa and <sup>2,3</sup>Heriberto Fernandez

<sup>1</sup>Departamento de Ciencias de la Salud, Seccion Genetica Humana,  
Microbiologia y Bioquimica Clinica, Universidad Tecnica Particular de Loja, Loja, Ecuador

<sup>2</sup>Instituto de Microbiologia Clinica,

Facultad de Medicina, Universidad Austral de Chile, Valdivia, Chile

<sup>3</sup>Programa Prometeo, SENESCYT, Ecuador

---

**Abstract:** This study was carried out to determine the prevalence and antimicrobial resistance of *Campylobacter jejuni* and *C. coli* from chicken livers sold for human consumption at public markets of Loja City, Southern Ecuador. *Campylobacter* sp. was isolated from 32 (62.7%) of 51 chicken liver samples. The 22 (68.8%) yielded *C. jejuni* and 10 (31.2%) *C. coli*. Among the isolated strains, high resistant frequencies were observed with ciprofloxacin (98.3%) and tetracycline (78.1%). Resistance to ampicillin and erythromycin was 25 and 12.5%, respectively. Multi-resistance (resistance to three or more antibiotics) was found in 9 (28.1%) strains. To our knowledge, this is the first attempt to demonstrate the presence of *Campylobacter* species and their antimicrobial susceptibility patterns in foodstuff in Southern Ecuador.

**Key words:** *Campylobacter*, chicken livers, antimicrobial resistance, diarrhea, epidemiology

---

### INTRODUCTION

The binomium *Campylobacter jejuni/C. coli* is considered worldwide as a major etiological agent in human diarrheal disease, being the leading cause of zoonotic food borne intestinal illness in industrialized countries and the second or third cause in developing countries (WHO, 2013; Fernandez, 2011).

Transmission of *C. jejuni* and *C. coli* to human beings includes consumption of contaminated water and food of animal origin, handling of raw chicken and other poultry meats or offal and direct contact with animals or their feces (WHO, 2013; Fernandez, 2011). Chicken liver could be of risk acquiring *Campylobacter* enteritis and several outbreaks have been reported due to the consumption of raw or under cooked liver or liver preparations such as pate or liver parfait (Whyte *et al.*, 2006; O'Leary *et al.*, 2009; Inms *et al.*, 2010; Little *et al.*, 2010; CDCP, 2013).

Besides food contamination as a risk factor for campylobacteriosis acquisition, the increasing of antimicrobial resistance rates among *Campylobacter* sp. is another issue of public health concern (Wang *et al.*, 2011; WHO, 2013; Whiley *et al.*, 2013). In South American countries, the emergence of *C. jejuni* and *C. coli* strains isolated from humans and animals, resistant to erythromycin, tetracycline, ampicillin and quinolones has

been widely reported where quinolone-resistant strains reached high rates, sometimes exceeding 60% (Fernandez, 2011; Pollett *et al.*, 2012).

The aims of this study were to determine the prevalence of *C. jejuni* and *C. coli* in chicken livers for human consumption sold in public markets of Loja City, Southern Ecuador (3°59' Southlatitude S; 79°12' West longitude) and to determine the susceptibility and resistance patterns of the isolated strains to six antimicrobial drugs.

### MATERIALS AND METHODS

A total of 51 chicken liver samples were obtained from the public markets of Loja City. Each sample consisting of four to five livers was ashed with 150 mL of Preston Enrichment Broth (CM 67 Oxoid enriched with 5% horse blood) and then was incubated at 42°C for 48 h in microaerophilic conditions. After that, 200 µL aliquots of the sample-enriched broth were filtrated onto Butzler agar plates using 0.45 µ filters (Fernandez *et al.*, 2007). All the plates were incubated under the same conditions as described above.

*Campylobacter* species were identified through their phenotypic characteristics using Gram stain, tests for catalase, oxidase, oxygen tolerance and growth at 25°C,

hippurate and indoxyl acetate hydrolysis tests and cephalothin and nalidixic acid as previously used by Fernandez and Arnas (1985) and Varela *et al.* (2007).

Susceptibility to ampicillin, amoxicillin/clavulanic acid, erythromycin, tetracycline, ciprofloxacin and gentamycin was determined by the Disk Diffusion Method following the 2014 recommendations of The European Committee on Antimicrobial Susceptibility Testing-EUCAST and the Committee for the Antibiogram of the French Society of Microbiology.

**RESULTS AND DISCUSSION**

Of the 51 samples, *Campylobacter* sp. was isolated from 32 (62.7%), of which 22 (68.8%) yielded *C. jejuni* and 10 (31.2%) *C. coli*.

As shown in Table 1, high resistant frequencies for *Campylobacter* sp. were observed with ciprofloxacin (98.3%) and tetracycline (78.1%) whereas 25 and 12.5% of the strains were resistant to ampicillin and erythromycin, respectively. One strain (3.1%) was resistant to gentamycin. Multi-resistance (resistance to three or more antibiotics) was found in 9 (28.1%) strains, in particular 3 strains were shown to be resistant to ampicillin, tetracycline and ciprofloxacin, 2 to erythromycin, tetracycline and ciprofloxacin, 1 to ampicillin, erythromycin, tetracycline and ciprofloxacin and 1 to ampicillin, erythromycin, tetracycline, ciprofloxacin and gentamycin.

Studies on prevalence data of *Campylobacter* in chicken livers have been carried out in several countries with reported isolation frequencies ranging from 15.5% in Bulgaria (Vashin *et al.*, 2009) 24% in South Africa (Bartkowiak-Higgo *et al.*, 2006), 72% in Turkey (Kenar *et al.*, 2009) to 92.9% in Chile (Fernandez and Pison, 1996) and 100% in New Zealand (Whyte *et al.*, 2006). In our study, the *Campylobacter* isolation rate was higher than that reported by Vashin *et al.* (2009) in Bulgaria and by Bartkowiak-Higgo *et al.* (2006) in South Africa.

However, it was lower than in reports coming from Turkey, Chile and New Zealand (Kenar *et al.*, 2009; Fernandez and Pison, 1996; Whyte *et al.*, 2006). In agreement with the studies of Whyte *et al.* (2006) and Kenar *et al.* (2009) *C. jejuni* was the predominant species with an isolation rate of 68.8% whereas *C. coli* was isolated in 31.2% of the studied samples. However, the opposite was found by Fernandez and Pison (1996) and Vashin *et al.* (2009) who have found that *C. coli* was most frequently isolated than *C. jejuni*.

Like chicken meat, offal could be source of *Campylobacter* infection (WHO, 2013). Outbreaks of *Campylobacter* are apparently uncommon. However, outbreaks of *Campylobacter enteritis* linked to raw or lightly cooked chicken livers (Whyte *et al.*, 2006; CDCP, 2013) or to food preparations like chicken liver pate (O’Leary *et al.*, 2009; Little *et al.*, 2010) and chicken liver parfait (Inns *et al.*, 2010) have been reported. This could be explained by the notion that chicken livers could contain a most probable number of *Campylobacter* >104 per liver (Whyte *et al.*, 2006) or levels ranging from 10 to >230 *Campylobacter* cells/100 mL of liquid exuded by livers (Fernandez and Pison, 1996), representing a potential source of human campylobacteriosis.

With regard to antimicrobial susceptibility, all the strains tested were susceptible to amoxicillin/clavulanic acid but 25% were resistant to ampicillin. Resistance to ampicillin and other  $\beta$ -lactam antibiotics has been reported among *Campylobacter* strains isolated from humans and poultry (Griggs *et al.*, 2009). Since, all the ampicillin-resistant strains found in our study were susceptible to amoxicillin/clavulanic acid, the resistance of these strains could be due to a  $\beta$ -lactamase production. The association amoxicillin/clavulanic acid has been proposed as a treatment choice in case of *Campylobacter enteritis* due to resistance of tested strains to the first-line antibiotics (Griggs *et al.*, 2009). Ampicillin resistance in *Campylobacter* strains of Southern Ecuador is likely to be an emerging problem that could require the establishment of a laboratory surveillance system to assess its real magnitude.

Table 1: Prevalence of antimicrobial resistance among *C. jejuni* and *C. coli* isolated from chicken livers used for human consumption

Antibiotics	<i>C. jejuni</i> strains (n = 22)				<i>C. coli</i> strains (n = 10)				Global resistance*	
	Resistant		Susceptible		Resistant		Susceptible		No.	%
	No.	%	No.	%	No.	%	No.	%		
Ampicillin	6	27.3	16	72.7	3	30.0	7	70.0	8	25.0
Amoxicillin/Clavulanic acid	0	0.0	22	100.0	0	0.0	10	100.0	0	0.0
Tetracycline	18	81.8	4	18.2	7	70.0	3	3.0	25	78.1
Ciprofloxacin	20	90.9	2	9.1	10	100.0	0	0.0	30	93.8
Erythromycin	2	9.1	20	90.9	2	20.0	8	80.0	4	12.5
Gentamycin	0	0.0	22	100.0	1	10.0	9	90.0	1	3.1

\**C. jejuni* + *C. coli* resistance

Only one *C. coli* strain was resistant to gentamycin. However, gentamycin-resistant strains have been isolated from chicken products (Noormohamed and Fakhr, 2012). In general terms, >99% of *C. jejuni* and 88% of *C. coli* isolates are susceptible to aminoglycosides while their resistance could be due to a modification of the antibiotic by aminoglycoside-modifying enzymes (Iovine, 2013).

Erythromycin resistance reaches 12.5% which is lower to that reported by Noormohamed and Fakhr (2012). However, since this antibiotic is the drug of choice (WHO, 2013) to treat *Campylobacter* enteritis, there is a necessity to create a laboratory surveillance and monitoring system for the adequate use of erythromycin in human medicine.

Tetracycline resistance was very high (78.1%) but lower to the levels obtained by Noormohamed and Fakhr (2012). The known mechanisms of tetracycline resistance in *Campylobacter* are alteration of tetracycline's ribosomal target and efflux and their high resistance frequency is likely due to the heavy use of this antibiotic in the past in both human and veterinary clinical practices (Iovine, 2013).

Surprisingly there was a remarkably high resistance rate to ciprofloxacin (93.8%), probably reflecting the overuse of fluoroquinolones in animals and in the poultry industry and representing an emerging worldwide epidemiological problem with implications for treatment in humans (WHO, 2013; Iovine, 2013).

All the *C. coli* strains were resistant to ciprofloxacin and always more resistant than *C. jejuni* to the other antibiotics with the exception of tetracycline. It is known that *C. coli* isolates are generally more resistant than *C. jejuni* strains (Gallay *et al.*, 2007).

Due to high *Campylobacter* isolation rates we found in chicken livers, a special attention must be paid to good practices in handling this foodstuff at groceries in order to minimize cross contamination with other foodstuffs, utensils and surfaces. The further studies potentially needed to assess the risk factors of *Campylobacter* contamination in the production chain, maintenance and sales processes of chicken livers for human consumption.

## CONCLUSION

To our knowledge, this is the first attempt to demonstrate the presence of *Campylobacter* species in foodstuff in Southern Ecuador as well as their antimicrobial susceptibility patterns.

## ACKNOWLEDGEMENTS

This research was supported by Project PRO\_CCNN\_863 UTPL 98739155. H.F. was supported by

the Prometeo Project of the Secretariat for Higher Education, Science, Technology and Innovation of the Republic of Ecuador. Thanks are given to Dr. Edward Ratovitski (Johns Hopkins University School of Medicine) for their scientific advices and critical review.

## REFERENCES

- Bartkowiak-Higgo, A.J., C.M. Veary, E.H. Venter and A.M. Bosman, 2006. A pilot study on post-evisceration contamination of broiler carcasses and ready-to-sell livers and intestines (mala) with *Campylobacter jejuni* and *Campylobacter coli* in a high-throughput South African poultry abattoir. J. South Afr. Vet. Assoc., 77: 114-119.
- CDCP., 2013. Multistate outbreak of *Campylobacter jejuni* infections associated with undercooked chicken livers-Northeastern United States, 2012. Morb. Mortal Wkly Rep., 62: 874-876.
- Fernandez, H. and V. Arnes, 1985. Occurrence of *Campylobacter jejuni* in dog FAECES from the streets of a Southern Chilean city. Rev. Inst. Med. Trop. Sao Paulo, 28: 410-412.
- Fernandez, H. and V. Pison, 1996. Isolation of enteropathogenic thermotolerant species of *Campylobacter* from commercial chicken livers. Int. J. Food Microbiol., 29: 75-80.
- Fernandez, H., 2011. *Campylobacter* y campylobacteriosis: Una mirada desde America del Sur [Campylobacter and campylobacteriosis: A view from South America]. Revista Peruana de Medicina Experimental y Salud Publica, 28: 121-127.
- Fernandez, H., F. Vera and M.P. Villanueva, 2007. *Arcobacter* and *Campylobacter species* in birds and mammals from Southern Chile. Arch. Med. Vet., 39: 163-165.
- Gallay, A., V. Prouzet-Mauleon, I. Kempf, P. Lehours and L. Labadi *et al.*, 2007. *Campylobacter* antimicrobial drug resistance among humans, broiler chickens and pigs, France. Emerg. Infect. Dis., 13: 259-266.
- Griggs, D.J., L. Peake, M.M. Johnson, S. Ghori, A. Mott and L.J. Piddock, 2009.  $\beta$ -lactamase-mediated  $\beta$ -lactam resistance in *Campylobacter* species: Prevalence of Cj0299 (blaOXA-61) and evidence for a novel  $\beta$ -lactamase in *C. jejuni*. Antimicrob. Agents Chemother., 53: 3357-3360.
- Inns, T., K. Foster and R. Gorton, 2010. Cohort study of a campylobacteriosis outbreak associated with chicken liver parfait, United Kingdom. Eurosurveillance, 15: 2-5.
- Iovine, N.M., 2013. Resistance mechanisms in *Campylobacter jejuni*. Virulence, 4: 230-240.

- Kenar, B., L. Akkaya and Y.O. Birdane, 2009. Prevalence of thermotolerant *Campylobacter* in chicken livers in Turkey and antimicrobial resistance among the *Campylobacter* strain. *J. Anim. Vet. Adv.*, 8: 853-856.
- Little, C.L., F.J. Gormley, N. Rawal and J.F. Richardson, 2010. A recipe for disaster: Outbreaks of campylobacteriosis associated with poultry liver pate in England and Wales. *Epidemiol. Infect.*, 138: 1691-1694.
- Noormohamed, A. and M.K. Fakhr, 2012. Incidence and antimicrobial resistance profiling of *Campylobacter* in retail chicken livers and gizzards. *Foodborne Path. Dis.*, 9: 617-624.
- O'Leary, M.C., O. Harding, L. Fisher and J. Cowden, 2009. A continuous common-source outbreak of campylobacteriosis associated with changes to the preparation of chicken liver pate. *Epidemiol. Infect.*, 137: 383-388.
- Pollett, S., C. Rocha, R. Zerpa, L. Patino and A. Valencia *et al.*, 2012. *Campylobacter* antimicrobial resistance in Peru: A ten-year observational study. *BMC Infect. Dis.* 10.1186/1471-2334-12-193.
- Varela, N.P., R. Friendship and C. Dewey, 2007. Prevalence of resistance to 11 antimicrobials among *Campylobacter coli* isolated from pigs on 80 grower-finisher farms in Ontario. *Can. J. Vet. Res.*, 71: 189-194.
- Vashin, I., T. Stoyanchev, C. Ring and V. Atanassova, 2009. Prevalence of *Campylobacter* sp. in frozen poultry at Bulgarian retail markets. *Trak. J. Sci.*, 7: 55-57.
- WHO., 2013. The global view of campylobacteriosis: Report of an expert consultation. World Health Organization, Document Production Services, Geneva, Switzerland.
- Wang, X., S. Zhao, H. Harbottle, T. Tran, K. Blickenstaff, J. Abbott and J. Meng, 2011. Antimicrobial resistance and molecular subtyping of *Campylobacter jejuni* and *Campylobacter coli* from retail meats. *J. Food. Prot.*, 74: 616-621.
- Whiley, H., B. van den Akker, S. Giglio and R. Bentham, 2013. The role of environmental reservoirs in human campylobacteriosis. *Int. J. Environ. Res. Public Health*, 10: 5886-5907.
- Whyte, R., J.A. Hudson and C. Graham, 2006. *Campylobacter* in chicken livers and their destruction by pan frying. *Lett. Applied Microbiol.*, 43: 591-595.